title: FDA Oncology Committee debates Iressa's status following negative trial results.
authors.forename: Renee
authors.initials: R
authors.lastname: Twombly
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D011799:Quinazolines / Q000627:therapeutic use*; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib